New PI3K Inhibitors

HomeNew PI3K Inhibitors
Catalog No. Product Name Information
E1076 Linperlisib Linperlisibis a highly selective, orally bioavailable PI3Kδ inhibitor with an IC50 value of 6.4 nM, as disclosed in patent WO 2015055071 A1 (compound 10).
E1076 Linperlisib Linperlisibis a highly selective, orally bioavailable PI3Kδ inhibitor with an IC50 value of 6.4 nM, as disclosed in patent WO 2015055071 A1 (compound 10).
E1609 NVP-CLR457 NVP-CLR457 is an orally active, potent, and balanced inhibitor of pan-class I PI3K. NVP-CLR457 exhibits IC50 values of 12 ± 1.5 nM, 8.3 ± 1.0 nM, 8.3 ± 2.0 nM, 230 ± 31 nM, for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ. It shows a clear dose-dependent PK/PD/efficacy relationship and demonstrates antitumor activity.
E4605 Copanlisib dihydrochloride Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a selective and potent inhibitor of pan-class I PI3K. It significantly inhibits the catalytic activity of class I PI3K isoforms α, β, γ, and δ with IC50 of 0.5, 3.7, 6.4, and 0.7 nM, respectively. BAY 80-6946 exhibits potent antitumor activity in multiple cell-line–derived and patient-derived xenograft tumor models.
E8308 Alpelisib hydrochloride Alpelisib hydrochloride is a potent and selective inhibitor of PI3Kα with an IC50 of 0.005 μM, 1.2 μM, 0.29 μM, 0.25 μM for p110α, p110β, p110δ, p110γ, respectively. It exhibits good efficacy in inhibiting the growth of PI3Ka driven tumors and can be used in cancer research.
≡ All PI3K Inhibitors